New AI-Powered Free Company Valuation tool for any company in the world. Upload a PDF financial statement to receive an instant report with customizable forecasts, credit score, default probability and key financial metrics. Try Now for Free →
- Get an AI-powered company valuation or credit risk report in just 2 minutes
- Get reports of any company in the world with a financial statement in any language
- Upload a PDF financial statement to receive an instant report with customizable forecasts, credit score, default probability and key financial metrics
Ascendis Pharma Growth Disorders A/S — Credit Rating and Financial Key Figures
Credit rating
Company information
About Ascendis Pharma Growth Disorders A/S
Ascendis Pharma Growth Disorders A/S (CVR number: 32323677) is a company from GENTOFTE. The company recorded a gross profit of -190726 kEUR in 2025. The operating profit was -222.6 mEUR, while net earnings were -225.7 mEUR. The profitability of the company measured by Return on Assets (ROA) was -32.3 %, which can be considered poor and Return on Equity (ROE) was -1231.8 %, which can be considered poor. The equity ratio, a key indicator for solidity, stood at -96.3 %. This indicates that the company's debt surpasses the value of its total assets, posing significant financial risk. Ascendis Pharma Growth Disorders A/S's liquidity measured by quick ratio was 0 which is at a very low level. Thus, the company is in an unstable financial position, with its liquid assets significantly undermatching its current liabilities. This severe liquidity deficiency may lead to financial distress and threaten the company's operational continuity.
Financial information
See financialsGross profit (kEUR)
EBIT (kEUR)
Profitability
Solidity
Key figures (kEUR)
See financials2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|
| Volume | |||||
| Net sales | |||||
| Gross profit | -47 933.48 | -57 035.67 | - 114 185.00 | - 157 522.00 | - 190 726.00 |
| EBIT | -48 049.95 | -57 152.13 | - 114 215.00 | - 157 591.00 | - 222 622.00 |
| Net earnings | -50 957.88 | -61 381.17 | - 120 223.00 | - 176 019.00 | - 225 725.00 |
| Shareholders equity total | - 140 441.79 | - 201 822.96 | - 322 046.00 | - 498 015.00 | - 723 740.00 |
| Balance sheet total (assets) | 9 546.00 | 13 615.38 | 21 622.00 | 8 933.00 | 27 717.00 |
| Net debt | 149 971.40 | 215 424.97 | 330 689.00 | 506 879.00 | 751 409.00 |
| Profitability | |||||
| EBIT-% | |||||
| ROA | -38.4 % | -31.3 % | -40.8 % | -37.0 % | -32.3 % |
| ROE | -502.6 % | -530.0 % | -682.4 % | -1152.1 % | -1231.8 % |
| ROI | -38.9 % | -31.3 % | -40.8 % | -37.0 % | -32.3 % |
| Economic value added (EVA) | -48 327.04 | -57 561.14 | - 114 734.76 | - 158 166.70 | - 200 027.99 |
| Solvency | |||||
| Equity ratio | -93.6 % | -93.7 % | -93.7 % | -98.2 % | -96.3 % |
| Gearing | -106.8 % | -106.7 % | -106.7 % | -101.8 % | -103.8 % |
| Relative net indebtedness % | |||||
| Liquidity | |||||
| Quick ratio | 188.4 | 874.8 | 1 883.3 | 49.4 | 0.0 |
| Current ratio | 188.4 | 874.8 | 1 883.3 | 49.4 | 0.0 |
| Cash and cash equivalents | 10.51 | 7.45 | 12 972.00 | 59.00 | 25.00 |
| Capital use efficiency | |||||
| Trade debtors turnover (days) | |||||
| Net working capital % | |||||
| Credit risk | |||||
| Credit rating | B | B | B | B | B |
Variable visualization
Roles
Companies in the same industry
- Company information
- Financial data
- Credit risk data
- All 400,000+ Danish companies
- Professional credit risk reports
- Create your own estimates for any company
- Valuation analysis
- All 400,000+ Danish companies
- See instructions
... and more!
No registration needed.